Report Detail
Global Nirsevimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4733787 |
- 24 August, 2026 |
- Global |
- 79 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Nirsevimab market size was valued at US$ 3035 million in 2025 and is forecast to a readjusted size of US$ 9852 million by 2032 with a CAGR of 18.3% during review period.
In 2025, global Nirsevimab production reached approximately 12 million units.Nirsevimab is a long-acting human immunoglobulin G1 kappa monoclonal antibody targeting the fusion protein of respiratory syncytial virus. It is designed to provide direct and rapid passive immune protection by binding to the prefusion conformation of the RSV F protein, thereby inhibiting viral fusion with host cell membranes and preventing subsequent infection. Approved for use in neonates and infants during their first RSV season, it offers a convenient single-dose administration and an extended half-life to sustain protection throughout the high-risk period, representing an important preventive option for respiratory syncytial virus infection in the pediatric population
Nirsevimab has established a dominant and rapidly expanding position in the global RSV prophylactic market, driven by its transformative clinical profile and unmet medical need. As a long-acting, single-dose monoclonal antibody, it addresses critical limitations of previous therapies by providing immediate, sustained protection for infants through an entire RSV season, fundamentally shifting clinical practice and public health strategies. Its market penetration is fueled by widespread regulatory approvals, formal inclusion in national pediatric immunization guidelines across major markets, and strong real-world evidence demonstrating significant reductions in infant hospitalizations. Despite intensifying competition from emerging RSV antibodies and maternal vaccines, nirsevimab maintains a leading edge through established brand recognition, optimized global supply chains, and expanded geographic reach into high-potential emerging markets. The market landscape continues to evolve with ongoing efforts to balance supply with surging global demand, adapt to evolving clinical recommendations, and navigate pricing and access dynamics across diverse healthcare systems, solidifying its role as a cornerstone in pediatric RSV prevention.
This report is a detailed and comprehensive analysis for global Nirsevimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Nirsevimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Nirsevimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Nirsevimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Nirsevimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Nirsevimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Nirsevimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Sanofi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Nirsevimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
50 mg (0.5 mL) / syringe
100 mg (1.0 mL) / syringe
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Route of Administration
Intramuscular Injection
Subcutaneous Injection
Market segment by Application
Prevention Of Respiratory Syncytial Virus Infection
Reduction Of Severe Lower Respiratory Tract Disease
Protection Of Infants During Rsv Season
Others
Major players covered
AstraZeneca
Sanofi
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nirsevimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nirsevimab, with price, sales quantity, revenue, and global market share of Nirsevimab from 2021 to 2026.
Chapter 3, the Nirsevimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nirsevimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Nirsevimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nirsevimab.
Chapter 14 and 15, to describe Nirsevimab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Nirsevimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 50 mg (0.5 mL) / syringe
- 1.3.3 100 mg (1.0 mL) / syringe
- 1.4 Market Analysis by Sales Channels
- 1.4.1 Overview: Global Nirsevimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital
- 1.4.3 Retail
- 1.4.4 Online
- 1.5 Market Analysis by Route of Administration
- 1.5.1 Overview: Global Nirsevimab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
- 1.5.2 Intramuscular Injection
- 1.5.3 Subcutaneous Injection
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Nirsevimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Prevention Of Respiratory Syncytial Virus Infection
- 1.6.3 Reduction Of Severe Lower Respiratory Tract Disease
- 1.6.4 Protection Of Infants During Rsv Season
- 1.6.5 Others
- 1.7 Global Nirsevimab Market Size & Forecast
- 1.7.1 Global Nirsevimab Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Nirsevimab Sales Quantity (2021-2032)
- 1.7.3 Global Nirsevimab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 AstraZeneca
- 2.1.1 AstraZeneca Details
- 2.1.2 AstraZeneca Major Business
- 2.1.3 AstraZeneca Nirsevimab Product and Services
- 2.1.4 AstraZeneca Nirsevimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 AstraZeneca Recent Developments/Updates
- 2.2 Sanofi
- 2.2.1 Sanofi Details
- 2.2.2 Sanofi Major Business
- 2.2.3 Sanofi Nirsevimab Product and Services
- 2.2.4 Sanofi Nirsevimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Sanofi Recent Developments/Updates
3 Competitive Environment: Nirsevimab by Manufacturer
- 3.1 Global Nirsevimab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Nirsevimab Revenue by Manufacturer (2021-2026)
- 3.3 Global Nirsevimab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Nirsevimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Nirsevimab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Nirsevimab Manufacturer Market Share in 2025
- 3.5 Nirsevimab Market: Overall Company Footprint Analysis
- 3.5.1 Nirsevimab Market: Region Footprint
- 3.5.2 Nirsevimab Market: Company Product Type Footprint
- 3.5.3 Nirsevimab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Nirsevimab Market Size by Region
- 4.1.1 Global Nirsevimab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Nirsevimab Consumption Value by Region (2021-2032)
- 4.1.3 Global Nirsevimab Average Price by Region (2021-2032)
- 4.2 North America Nirsevimab Consumption Value (2021-2032)
- 4.3 Europe Nirsevimab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Nirsevimab Consumption Value (2021-2032)
- 4.5 South America Nirsevimab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Nirsevimab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Nirsevimab Sales Quantity by Type (2021-2032)
- 5.2 Global Nirsevimab Consumption Value by Type (2021-2032)
- 5.3 Global Nirsevimab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Nirsevimab Sales Quantity by Application (2021-2032)
- 6.2 Global Nirsevimab Consumption Value by Application (2021-2032)
- 6.3 Global Nirsevimab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Nirsevimab Sales Quantity by Type (2021-2032)
- 7.2 North America Nirsevimab Sales Quantity by Application (2021-2032)
- 7.3 North America Nirsevimab Market Size by Country
- 7.3.1 North America Nirsevimab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Nirsevimab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Nirsevimab Sales Quantity by Type (2021-2032)
- 8.2 Europe Nirsevimab Sales Quantity by Application (2021-2032)
- 8.3 Europe Nirsevimab Market Size by Country
- 8.3.1 Europe Nirsevimab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Nirsevimab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Nirsevimab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Nirsevimab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Nirsevimab Market Size by Region
- 9.3.1 Asia-Pacific Nirsevimab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Nirsevimab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Nirsevimab Sales Quantity by Type (2021-2032)
- 10.2 South America Nirsevimab Sales Quantity by Application (2021-2032)
- 10.3 South America Nirsevimab Market Size by Country
- 10.3.1 South America Nirsevimab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Nirsevimab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Nirsevimab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Nirsevimab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Nirsevimab Market Size by Country
- 11.3.1 Middle East & Africa Nirsevimab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Nirsevimab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Nirsevimab Market Drivers
- 12.2 Nirsevimab Market Restraints
- 12.3 Nirsevimab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Nirsevimab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Nirsevimab
- 13.3 Nirsevimab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Nirsevimab Typical Distributors
- 14.3 Nirsevimab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Nirsevimab. Industry analysis & Market Report on Nirsevimab is a syndicated market report, published as Global Nirsevimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Nirsevimab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
